Suppr超能文献

患有bcl-2易位的非霍奇金淋巴瘤患者的骨髓,可使用单克隆抗体和免疫磁珠清除法,清除聚合酶链反应可检测到的淋巴瘤细胞。

Bone marrows of non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion.

作者信息

Gribben J G, Saporito L, Barber M, Blake K W, Edwards R M, Griffin J D, Freedman A S, Nadler L M

机构信息

Dana Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA 02115.

出版信息

Blood. 1992 Aug 15;80(4):1083-9.

PMID:1498325
Abstract

Using the extremely sensitive technique of polymerase chain reaction (PCR) to detect the bcl-2 translocation, only 50% of bone marrows could be purged of PCR-detectable lymphoma cells using a cocktail of three anti-B-cell monoclonal antibodies (MoAbs) and complement-mediated lysis. This observation is of clinical importance because those patients whose reinfused marrows harbored residual lymphoma cells showed a significantly increased incidence of relapse. To improve purging, we used PCR detection of the bcl-2 translocation to compare the efficiency of complement-mediated lysis with immunomagnetic bead depletion. Using either a three or a four MoAb cocktail followed by immunomagnetic bead depletion, all PCR-detectable cells were purged after three cycles of treatment. In these same patient samples, treatment with three MoAbs and complement purged only 11 of the 25 (44%) samples. The addition of a fourth MoAb followed by complement lysis purged the marrows of only an additional five patients. Immunomagnetic bead depletion was specific because there was no loss of committed myeloid progenitor cells. The above results suggest that immunomagnetic bead depletion of the harvested marrow will likely be superior to our previous method of purging and the lack of nonspecific toxicity to myeloid progenitor cells predicts that it will not impair engraftment. This methodology will now be used to determine whether the reinfusion of lymphoma free marrow affects the incidence of relapse after autologous bone marrow transplantation.

摘要

采用极其灵敏的聚合酶链反应(PCR)技术检测bcl-2易位,使用三种抗B细胞单克隆抗体(MoAbs)和补体介导的溶解的混合剂,仅50%的骨髓能清除PCR可检测到的淋巴瘤细胞。这一观察结果具有临床重要性,因为那些回输的骨髓中含有残留淋巴瘤细胞的患者复发率显著增加。为了改进清除效果,我们使用PCR检测bcl-2易位来比较补体介导的溶解与免疫磁珠去除的效率。使用三种或四种MoAbs混合剂后再进行免疫磁珠去除,经过三个治疗周期后,所有PCR可检测到的细胞都被清除了。在这些相同的患者样本中,用三种MoAbs和补体治疗仅清除了25个样本中的11个(44%)。添加第四种MoAbs后再进行补体溶解,仅又清除了另外5名患者的骨髓。免疫磁珠去除具有特异性,因为定向髓系祖细胞没有损失。上述结果表明,对采集的骨髓进行免疫磁珠去除可能优于我们先前的清除方法,并且对髓系祖细胞缺乏非特异性毒性预示着它不会损害植入。现在将使用这种方法来确定回输无淋巴瘤骨髓是否会影响自体骨髓移植后的复发率。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验